DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ttvlcb/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Japan Drug Forecast and Market Analysis to 2023" report to their offering.
The migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
The launch of drugs in the Japanese market is often delayed due to the requirement by Japanese regulatory agencies to perform clinical studies in Japanese patients; as a result, the market uptake of lasmiditan and MK-1602 will occur at the very end of the forecast period, when they are expected to steal shares from triptans as well as gaining additional patient share from the underserved population.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
3.1 Etiology and Pathophysiology
4 Disease Management
4.1 Treatment Overview
5 Competitive Assessment
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands
6 Opportunity and Unmet Need
6.2 Unmet Needs Gap Analysis
7 Pipeline Assessment
7.2 Promising drugs in clinical development
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/ttvlcb/pharmapoint
Source: Research and Markets